ADC Therapeutics
IPO News: Filed F-1/A: ADC Therapeutics Launches 7.4mm share IPO with $16-$18 Marketing Range
ADC Therapeutics

ADC Therapeutics SA

NYSE:  ADCT

Initial Filing Date:  04/24/20

Launch Date:  05/11/20

Price Range:  $16.00 - $18.00

Shares Offered (Pre-Shoe | mm):  7.4

Primary Shares (mm):  7.4

Secondary Shares (mm):  0.0

Size (mm):  $125.0

% Secondary:  0.0%

Shares Outstanding (mm):  63.9

Market Value at Midpoint (mm):  $1,086.8

Offering as % of Market Value:  11.5%

Bookrunners:  Morgan Stanley | BofA | Cowen

Major Holders:  Auven Therapeutics | AstraZeneca (UK) | HPWH | Redmile Group

Description:  ADC Therapeutics is a late clinical-stage oncology-focused biotechnology company evolving into a commercial-stage company as they prepare for the launch of their lead product candidate, if approved. They are a pioneer in the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors.

Note:  Emerging Growth Company

 

Reference Link:  F-1/A